ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

GreenLight Biosciences raises $17m from Malaysia fund for vaccine

US company earmarks new money for 'affordable' coronavirus treatment

Muslims disperse after they were warned by police outside the closed National Mosque while celebrating the Muslim festival marking the end of Ramadan amid the coronavirus outbreak in Kuala Lumpur.   © Reuters

SINGAPORE -- U.S.-based bio-performance company GreenLight Biosciences has raised an additional $17 million from new and existing investors, including Malaysian private investment company Xeraya Capital, Baird Capital and global investment company Flu Lab, according to a media statement.

The investment was made through Greenlight Pandemic Response, a special purpose vehicle of GreenLight Biosciences, Xeraya Capital CEO Fares Zahir told DealStreetAsia.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more